Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161091 | 0.79 | SIGMAR1 (0.35) | — | |
| SCHEMBL18900144 | 0.74 | LTA4H (0.42) | — | |
| SCHEMBL12690466 | 0.73 | CYP1A2 (0.38) | — | |
| SCHEMBL18900347 | 0.70 | LTA4H (0.46) | — | |
| SCHEMBL1437449 | 0.70 | LMNA (0.31) | LMNAMAPTKDM4E | |
| SCHEMBL12812615 | 0.69 | PSMB1 (0.42) | LMNAALDH1A1KDM4E | |
| SCHEMBL1437799 | 0.69 | LMNA (0.32) | LMNAKDM4E | |
| SCHEMBL525962 | 0.67 | TAAR1 (0.42) | KDM4EKCNH2 | |
| SCHEMBL525971 | 0.66 | LMNA (0.30) | LMNA | |
| SCHEMBL2610786 | 0.65 | NOS3 (0.39) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI SA (FR) | 2014-06-05 | — | — | US | disclosed |
| EP-2470547-B1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| EP-2470547-B1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-8481042-B2 | Conjugates of pyrrolo[1,4]benzodiazepine dimers as anticancer agents | SANOFI (FR) | 2013-07-09 | — | — | US | disclosed |
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| EP-2470547-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI (FR) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011023883-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011023883-A1 | CONJUGATES OF PYRROLO[1,4]BENZODIAZEPINE DIMERS AS ANTICANCER AGENTS | SANOFI-AVENTIS (FR) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120244172-A1 | Conjudates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | GABRA4, GABRA1, GABRA2 | LMNA 4159/4885CHRNB2 912/4885CHRNA4 178/4885 |
| US-20140155590-A1 | Conjugates of Pyrrolo[1,4]Benzodiazepine Dimers As Anticancer Agents | GABRA4, GABRP, GABRA1 | LMNA 4055/4885CHRNB2 1179/4885CHRNA4 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.